Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1989 Nov;44(11):971–977. doi: 10.1136/thx.44.11.971

AIDS and the lung. 2--Antiretroviral treatment in human immunodeficiency virus disease.

A J Pinching 1
PMCID: PMC462157  PMID: 2556809

Full text

PDF
971

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azidothymidine in the treatment of AIDS. N Engl J Med. 1988 Jan 28;318(4):250–251. doi: 10.1056/NEJM198801283180412. [DOI] [PubMed] [Google Scholar]
  2. Bach M. C. Zidovudine for lymphocytic interstitial pneumonia associated with AIDS. Lancet. 1987 Oct 3;2(8562):796–796. doi: 10.1016/s0140-6736(87)92524-4. [DOI] [PubMed] [Google Scholar]
  3. Bergdahl S., Sönnerborg A., Larsson A., Strannegard O. Declining levels of HIV P24 antigen in serum during treatment with foscarnet. Lancet. 1988 May 7;1(8593):1052–1052. doi: 10.1016/s0140-6736(88)91867-3. [DOI] [PubMed] [Google Scholar]
  4. Bessen L. J., Greene J. B., Louie E., Seitzman P., Weinberg H. Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC. N Engl J Med. 1988 Mar 17;318(11):708–708. doi: 10.1056/nejm198803173181113. [DOI] [PubMed] [Google Scholar]
  5. Brook M. G., Gor D., Forster S. M., Harris W., Jeffries D. J., Thomas H. C. Suppression of HIV p24 antigen and induction of HIV anti-p24 antibody by alpha interferon in patients with chronic hepatitis B. AIDS. 1988 Oct;2(5):391–393. [PubMed] [Google Scholar]
  6. Capon D. J., Chamow S. M., Mordenti J., Marsters S. A., Gregory T., Mitsuya H., Byrn R. A., Lucas C., Wurm F. M., Groopman J. E. Designing CD4 immunoadhesins for AIDS therapy. Nature. 1989 Feb 9;337(6207):525–531. doi: 10.1038/337525a0. [DOI] [PubMed] [Google Scholar]
  7. Deen K. C., McDougal J. S., Inacker R., Folena-Wasserman G., Arthos J., Rosenberg J., Maddon P. J., Axel R., Sweet R. W. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature. 1988 Jan 7;331(6151):82–84. doi: 10.1038/331082a0. [DOI] [PubMed] [Google Scholar]
  8. Farthing C. F., Dalgleish A. G., Clark A., McClure M., Chanas A., Gazzard B. G. Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex. AIDS. 1987 May;1(1):21–25. [PubMed] [Google Scholar]
  9. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  10. Fisher R. A., Bertonis J. M., Meier W., Johnson V. A., Costopoulos D. S., Liu T., Tizard R., Walker B. D., Hirsch M. S., Schooley R. T. HIV infection is blocked in vitro by recombinant soluble CD4. Nature. 1988 Jan 7;331(6151):76–78. doi: 10.1038/331076a0. [DOI] [PubMed] [Google Scholar]
  11. Gaub J., Pedersen C., Poulsen A. G., Mathiesen L. R., Ulrich K., Lindhardt B. O., Faber V., Gerstoft J., Hofmann B., Lernestedt J. O. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. AIDS. 1987 May;1(1):27–33. [PubMed] [Google Scholar]
  12. Glatt A. E., Chirgwin K., Landesman S. H. Current concepts. Treatment of infections associated with human immunodeficiency virus. N Engl J Med. 1988 Jun 2;318(22):1439–1448. doi: 10.1056/NEJM198806023182206. [DOI] [PubMed] [Google Scholar]
  13. Gold J. W. Infectious complications in patients with HIV infection. AIDS. 1988 Oct;2(5):327–334. doi: 10.1097/00002030-198810000-00001. [DOI] [PubMed] [Google Scholar]
  14. Grimm G., Ferenci P., Katzenschlager R., Madl C., Schneeweiss B., Laggner A. N., Lenz K., Gangl A. Improvement of hepatic encephalopathy treated with flumazenil. Lancet. 1988 Dec 17;2(8625):1392–1394. doi: 10.1016/s0140-6736(88)90587-9. [DOI] [PubMed] [Google Scholar]
  15. Helbert M., Fletcher T., Peddle B., Harris J. R., Pinching A. J. Zidovudine-associated myopathy. Lancet. 1988 Sep 17;2(8612):689–690. doi: 10.1016/s0140-6736(88)90506-5. [DOI] [PubMed] [Google Scholar]
  16. Helbert M., Robinson D., Peddle B., Forster S., Kocsis A., Jeffries D., Pinching A. J. Acute meningo-encephalitis on dose reduction of zidovudine. Lancet. 1988 Jun 4;1(8597):1249–1252. doi: 10.1016/s0140-6736(88)92072-7. [DOI] [PubMed] [Google Scholar]
  17. Helbert M., Stoneham C., Mitchell D., Pinching A. J. Zidovudine for lymphocytic interstitial pneumonitis in AIDS. Lancet. 1987 Dec 5;2(8571):1333–1333. doi: 10.1016/s0140-6736(87)91223-2. [DOI] [PubMed] [Google Scholar]
  18. Hussey R. E., Richardson N. E., Kowalski M., Brown N. R., Chang H. C., Siliciano R. F., Dorfman T., Walker B., Sodroski J., Reinherz E. L. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature. 1988 Jan 7;331(6151):78–81. doi: 10.1038/331078a0. [DOI] [PubMed] [Google Scholar]
  19. Hymes K. B., Greene J. B., Karpatkin S. The effect of azidothymidine on HIV-related thrombocytopenia. N Engl J Med. 1988 Feb 25;318(8):516–517. doi: 10.1056/NEJM198802253180812. [DOI] [PubMed] [Google Scholar]
  20. Jackson G. G., Paul D. A., Falk L. A., Rubenis M., Despotes J. C., Mack D., Knigge M., Emeson E. E. Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT). Ann Intern Med. 1988 Feb;108(2):175–180. doi: 10.7326/0003-4819-108-2-175. [DOI] [PubMed] [Google Scholar]
  21. Jackson G. G., Perkins J. T., Rubenis M., Paul D. A., Knigge M., Despotes J. C., Spencer P. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet. 1988 Sep 17;2(8612):647–652. doi: 10.1016/s0140-6736(88)90468-0. [DOI] [PubMed] [Google Scholar]
  22. Karpas A., Hill F., Youle M., Cullen V., Gray J., Byron N., Hayhoe F., Tenant-Flowers M., Howard L., Gilgen D. Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9234–9237. doi: 10.1073/pnas.85.23.9234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lane H. C., Kovacs J. A., Feinberg J., Herpin B., Davey V., Walker R., Deyton L., Metcalf J. A., Baseler M., Salzman N. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1218–1222. doi: 10.1016/s0140-6736(88)90811-2. [DOI] [PubMed] [Google Scholar]
  24. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  25. Loke R. H., Wade J. P., Murray-Lyon I. M. Myelopathy after stopping zidovudine. Lancet. 1988 Jul 30;2(8605):279–279. doi: 10.1016/s0140-6736(88)92567-6. [DOI] [PubMed] [Google Scholar]
  26. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Necrotising myopathy and zidovudine. Lancet. 1988 May 7;1(8593):1050–1051. [PubMed] [Google Scholar]
  28. Orholm M., Pedersen C., Mathiesen L., Dowd P., Nielsen J. O. Suppression of p24 antigen in sera from HIV-infected individuals with low-dose alpha-interferon and zidovudine: a pilot study. AIDS. 1989 Feb;3(2):97–100. doi: 10.1097/00002030-198902000-00008. [DOI] [PubMed] [Google Scholar]
  29. Pinching A. J. Current issues in the management of AIDS patients. J Acquir Immune Defic Syndr. 1988;1(6):583–592. [PubMed] [Google Scholar]
  30. Pinching A. J. Factors affecting the natural history of human immunodeficiency virus infection. Immunodefic Rev. 1988;1(1):23–38. [PubMed] [Google Scholar]
  31. Pinching A. J., Helbert M., Peddle B., Robinson D., Janes K., Gor D., Jeffries D. J., Stoneham C., Mitchell D., Kocsis A. E. Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex. J Infect. 1989 Jan;18 (Suppl 1):33–40. doi: 10.1016/s0163-4453(89)80078-7. [DOI] [PubMed] [Google Scholar]
  32. Pinching A. J. Prophylactic and maintenance therapy for opportunist infections in AIDS. AIDS. 1988 Oct;2(5):335–343. doi: 10.1097/00002030-198810000-00002. [DOI] [PubMed] [Google Scholar]
  33. Pizzo P. A., Eddy J., Falloon J., Balis F. M., Murphy R. F., Moss H., Wolters P., Brouwers P., Jarosinski P., Rubin M. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988 Oct 6;319(14):889–896. doi: 10.1056/NEJM198810063191401. [DOI] [PubMed] [Google Scholar]
  34. Ragni M. V., Tama G., Lewis J. H., Ho M. Increased frequency of haemarthroses in haemophilic patient treated with zidovudine. Lancet. 1988 Jun 25;1(8600):1454–1455. doi: 10.1016/s0140-6736(88)92259-3. [DOI] [PubMed] [Google Scholar]
  35. Richman D. D., Andrews J. Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection. Am J Med. 1988 Aug 29;85(2A):208–213. [PubMed] [Google Scholar]
  36. Schmitt F. A., Bigley J. W., McKinnis R., Logue P. E., Evans R. W., Drucker J. L. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1988 Dec 15;319(24):1573–1578. doi: 10.1056/NEJM198812153192404. [DOI] [PubMed] [Google Scholar]
  37. Smith D. H., Byrn R. A., Marsters S. A., Gregory T., Groopman J. E., Capon D. J. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science. 1987 Dec 18;238(4834):1704–1707. doi: 10.1126/science.3500514. [DOI] [PubMed] [Google Scholar]
  38. Stambuk D., Hawkins D., Gazzard B. G. Zidovudine treatment of patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex: St Stephen's Hospital experience. J Infect. 1989 Jan;18 (Suppl 1):41–51. doi: 10.1016/s0163-4453(89)80079-9. [DOI] [PubMed] [Google Scholar]
  39. Traunecker A., Lüke W., Karjalainen K. Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature. 1988 Jan 7;331(6151):84–86. doi: 10.1038/331084a0. [DOI] [PubMed] [Google Scholar]
  40. Williams I., Gabriel G., Cohen H., Williams P., Tedder R. S., Machin S., Weller I. V. Zidovudine--the first year of experience. J Infect. 1989 Jan;18 (Suppl 1):23–31. doi: 10.1016/s0163-4453(89)80077-5. [DOI] [PubMed] [Google Scholar]
  41. Wofsy C. B. AIDS care: providing care for the HIV infected. J Acquir Immune Defic Syndr. 1988;1(3):274–283. [PubMed] [Google Scholar]
  42. Yarchoan R., Berg G., Brouwers P., Fischl M. A., Spitzer A. R., Wichman A., Grafman J., Thomas R. V., Safai B., Brunetti A. Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet. 1987 Jan 17;1(8525):132–135. doi: 10.1016/s0140-6736(87)91968-4. [DOI] [PubMed] [Google Scholar]
  43. Yarchoan R., Klecker R. W., Weinhold K. J., Markham P. D., Lyerly H. K., Durack D. T., Gelmann E., Lehrman S. N., Blum R. M., Barry D. W. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986 Mar 15;1(8481):575–580. doi: 10.1016/s0140-6736(86)92808-4. [DOI] [PubMed] [Google Scholar]
  44. Yarchoan R., Perno C. F., Thomas R. V., Klecker R. W., Allain J. P., Wills R. J., McAtee N., Fischl M. A., Dubinsky R., McNeely M. C. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988 Jan 16;1(8577):76–81. doi: 10.1016/s0140-6736(88)90283-8. [DOI] [PubMed] [Google Scholar]
  45. de Gans J., Lange J. M., Derix M. M., de Wolf F., Eeftinck Schattenkerk J. K., Danner S. A., Ongerboer de Visser B. W., Cload P., Goudsmit J. Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. AIDS. 1988 Feb;2(1):37–40. doi: 10.1097/00002030-198802000-00006. [DOI] [PubMed] [Google Scholar]
  46. de Wit R., Schattenkerk J. K., Boucher C. A., Bakker P. J., Veenhof K. H., Danner S. A. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1214–1217. doi: 10.1016/s0140-6736(88)90810-0. [DOI] [PubMed] [Google Scholar]
  47. de Wolf F., Lange J. M., Goudsmit J., Cload P., de Gans J., Schellekens P. T., Coutinho R. A., Fiddian A. P., van der Noordaa J. Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet. 1988 Feb 20;1(8582):373–376. doi: 10.1016/s0140-6736(88)91179-8. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES